Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Glatiramer acetate and interferon-beta throughout gestation and postpartum in women with multiple sclerosis.
A gradient in cortical pathology in multiple sclerosis by in vivo quantitative 7 T imaging.
Prolonged Toxic Encephalopathy following Accidental 4-Aminopyridine Overdose.
Guillain-Barré syndrome: clinical profile and management.
Single-use autoinjector for peginterferon-β1a treatment of relapsing-remitting multiple sclerosis: safety, tolerability and patient evaluation data from the Phase IIIb ATTAIN study.
Laquinimod (ABR-215062) suppresses the development of experimental autoimmune encephalomyelitis, modulates the Th1/Th2 balance and induces the Th3 cytokine TGF-beta in Lewis rats.
Combined central and peripheral demyelination: Clinical features, diagnostic findings, and treatment.
Laquinimod
Clinical and MRI characterization of MS patients with a pure and severe cognitive onset.
Spinal cord quantitative MRI discriminates between disability levels in multiple sclerosis.
Interferon beta 1b following natalizumab discontinuation: one year, randomized, prospective, pilot trial.
Balance impairment in people with multiple sclerosis: Preliminary evidence for the Balance Evaluation Systems Test.
Idebenone delays the onset of cardiac functional alteration without correction of Fe-S enzymes deficit in a mouse model for Friedreich ataxia.
Comparing the biological impact of glatiramer acetate with the biological impact of a generic.
Long-term safety and efficacy of teriflunomide: Nine-year follow-up of the randomized TEMSO study.
Puma, but not noxa is essential for oligodendroglial cell death.
Targeted Stage-Specific Inflammatory microRNA Profiling in Urine During Disease Progression in Experimental Autoimmune Encephalomyelitis: Markers of Disease Progression and Drug Response.
Anti-myelin oligodendrocyte glycoprotein antibodies in pediatric patients with optic neuritis.
Axonal and oligodendrocyte-localized IgM and IgG deposits in MS lesions.
Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P1R ) and receptor-5 (S1P5R ) agonist with autoimmune disease-modifying activity.
Fine-Mapping the Genetic Association of the Major Histocompatibility Complex in Multiple Sclerosis: HLA and Non-HLA Effects.
Daclizumab (anti-CD25) in multiple sclerosis.
Therapeutic effects of novel sphingosine-1-phosphate receptor agonist W-061 in murine DSS colitis.
Teva Announces U.S. Supreme Court Will Hear Its Appeal on COPAXONE(R) Patent
Early relapses, onset of progression, and late outcome in multiple sclerosis.

Pages